IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer
Zhi, Xiuyi1; Gao, Wen2; Han, Baohui3; Yang, Yue4; Li, Hui1; Liu, Deruo5; Wang, Changli6; Min, Gong1; Long, Hao7; Rigas, James R.8; Carey, Mark8; Jahan, Thierry9; Sammann, Amanda9; Reza, Joseph9; Wang, Daoyuan10; Mann, Michael J.9; Jablons, David M.9; He, Jianxing10; China Clinical Trials Consortium
关键词Non-small Cell Lung Cancer Adjuvant Chemotherapy Docetaxel Carboplatin
刊名JOURNAL OF THORACIC DISEASE
2013-10-01
DOI10.3978/j.issn.2072-1439.2012.02.05
5期:5页:578-584
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Respiratory System
资助者Sanofi-Aventis ; Sanofi-Aventis
研究领域[WOS]Respiratory System
关键词[WOS]VINORELBINE PLUS CISPLATIN ; RESECTED STAGE-I ; CLINICAL-TRIALS ; PHASE-II ; TUMORS
英文摘要

Background: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC).

Methods: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. The primary endpoint of the study was safety, as reflected by a febrile neutropenia rate of <10%. Other endpoints assessed protocol compliance and the impact of minimally invasive surgical technique.

Results: Patient accrual was completed at 1 center in the US and 10 centers in China in <6 months. Febrile neutropenia complicated treatment in 12 patients (9.0%), below the predetermined safety threshold of 14 patients. Four VATS and 8 open thoracotomy patients experienced febrile neutropenia (P=0.26). Completion of the three-cycle adjuvant regimen was achieved in 86% (95% CI, 77-95%) of patients. Sixty-two of 66 VATS patients compared to 53 of 67 open thoracotomy patients received all three doses according to protocol (P<0.01). Thirteen serious adverse events (9.8%) and no deaths were attributed to the study regimen.

Conclusions: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. Adjuvant treatment compliance was higher among patients undergoing a minimally invasive surgical approach.

语种英语
资助者Sanofi-Aventis ; Sanofi-Aventis
WOS记录号WOS:000328462500009
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58131
专题北京大学临床肿瘤学院
作者单位1.Capital Med Univ, Beijing Lung Canc Ctr, Beijing, Peoples R China
2.Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
3.Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
4.Peking Univ, Beijing Canc Hosp, Beijing 100871, Peoples R China
5.Beijing Sino Japan Hosp, Beijing, Peoples R China
6.Tianjin Med Univ, Tianjin Canc Hosp, Tianjin, Peoples R China
7.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
8.Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
9.Univ Calif San Francisco, San Francisco, CA 94143 USA
10.Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Zhi, Xiuyi,Gao, Wen,Han, Baohui,et al. VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer[J]. JOURNAL OF THORACIC DISEASE,2013,5(5):578-584.
APA Zhi, Xiuyi.,Gao, Wen.,Han, Baohui.,Yang, Yue.,Li, Hui.,...&China Clinical Trials Consortium.(2013).VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.JOURNAL OF THORACIC DISEASE,5(5),578-584.
MLA Zhi, Xiuyi,et al."VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer".JOURNAL OF THORACIC DISEASE 5.5(2013):578-584.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhi, Xiuyi]的文章
[Gao, Wen]的文章
[Han, Baohui]的文章
百度学术
百度学术中相似的文章
[Zhi, Xiuyi]的文章
[Gao, Wen]的文章
[Han, Baohui]的文章
必应学术
必应学术中相似的文章
[Zhi, Xiuyi]的文章
[Gao, Wen]的文章
[Han, Baohui]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。